Single Source for Continuation of the Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal (U01 Research Project (Cooperative Agreement) Clinical Trial not allowed)

The summary for the Single Source for Continuation of the Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal (U01 Research Project (Cooperative Agreement) Clinical Trial not allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Single Source for Continuation of the Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal (U01 Research Project (Cooperative Agreement) Clinical Trial not allowed): This non-competitive Notice of Funding Opportunity (NOFO) is intended to fund a single award to the current awardee institution of the Accelerating Medicines Partnership in Common Metabolic Diseases Knowledge Portal (AMP CMD KP), the Broad Institute, Inc. The AMP CMD program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time NOFO to provide funds to the AMP CMD KP to continue the development and maintenance of the web portal and underlying, curated knowledge base; which serves as the flagship resource encompassing the myriad types of data and information that provide an understanding of the biological heterogeneity in patients with CMDs and their related complications. In its next five-year period, the AMP CMD KP will be expected to continue its expansion of its datasets and traits, import additional data types, deploy additional analytical and visualization tools, and increase its utility to a more diverse user base, and to develop a framework for independent sustainability. The application will be peer-reviewed and if it is not a meritorious application, it will not be funded.